Hepatocellular Carcinoma

Woburn, Massachusetts | April 13, 2026 Sirtex Medical has announced groundbreaking results from its DOORwaY90 clinical study, demonstrating 100%...

CAMBRIDGE, UK, April 2, 2026 AstraZeneca has announced positive results from the Phase III EMERALD-3 trial, where a combination...

SHANGHAI, China, March 31, 2026 Abbisko Therapeutics has announced that its investigational FGFR4 inhibitor irpagratinib (ABSK-011) has been granted...

OTTAWA, Canada, February 2026 — Canada’s Drug Agency (CDA-AMC) has issued a conditional reimbursement recommendation for Opdivo® (nivolumab) plus...

Rockville, Md. and Shanghai, January 18, 2026 — AbelZeta Pharma, Inc. announced that AstraZeneca has agreed to acquire AbelZeta’s...